Yahoo Finance • last month

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; Decemb... Full story

Yahoo Finance • last month

How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter

Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus. Continue Reading... Full story

Yahoo Finance • last month

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors

Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable ass... Full story

Yahoo Finance • 2 months ago

Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (B... Full story

Yahoo Finance • 2 months ago

$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote – GES, PINC, PRO, and MRUS

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story

Yahoo Finance • 3 months ago

Merus (MRUS): Assessing Valuation After Recent 38% Stock Gain

Merus (MRUS) has seen its stock make steady gains recently, with shares climbing nearly 38% over the past month. Investors seem to be paying close attention to the company's impressive annual revenue growth and overall positive outlook. S... Full story

Yahoo Finance • 3 months ago

Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid

– 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd) – 62% responspercentage in 2L links- en rechtszijdige mCRC (n=13, bevestigd en onbevestigd) UTRECHT, Nederland en CAMBRIDGE, Massachusetts, Oct. 25, 2025... Full story

Yahoo Finance • 3 months ago

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWS... Full story

Yahoo Finance • 3 months ago

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

Media Release COPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”)... Full story

Yahoo Finance • 3 months ago

Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker

- In combinatie met FOLFOX/FOLFIRI (1L en 2L mCRC) en als monotherapie (3L+ mCRC) toont petosemtamab werkzaamheid tegen tumoren en een beheerbaar veiligheidsprofiel aan UTRECHT, Nederland en CAMBRIDGE, Massachusetts, Oct. 14, 2025 (GLOB... Full story

Yahoo Finance • 3 months ago

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 3 months ago

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 3 months ago

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger – PINC, ODP, PRO, and MRUS

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story

Yahoo Finance • 3 months ago

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 3 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

BALA CYNWYD, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 3 months ago

Notable healthcare headlines for the week: Pfizer, Novo Nordisk and JNJ in focus

Wall Street’s broader market averages closed mixed on Friday as market participants digested the U.S. government shutdown for the third day. For the week, the Dow, S&P 500, and Nasdaq Composite advanced by 1.1%, 1.08%, and 1.32%, respecti... Full story

Yahoo Finance • 3 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRO, EA, MRUS on Behalf of Shareholders

NEW YORK, Oct. 04, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 3 months ago

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger – VRNT, EA, MRUS, and The Farmers Savings Bank

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story

Yahoo Finance • 3 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA and MRUS on Behalf of Shareholders

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story